1375751-08-8

Usage

Uses

Used in Pharmaceutical Industry:
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one is used as a potential pharmaceutical drug due to its complex structure and the presence of multiple functional groups that may exhibit specific biological activities. (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one's unique stereochemistry and functional groups could be harnessed to target various diseases or conditions, making it a valuable asset in drug development.
Used in Research and Development:
In the field of research and development, (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one serves as a molecular probe for studying biological processes. Its distinct structure and functional groups allow researchers to investigate the interactions between the molecule and various biological targets, potentially leading to a better understanding of certain diseases and the development of novel therapeutic strategies.
Used in Drug Design and Optimization:
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one can be employed in the design and optimization of new drugs. Its unique structure and functional groups provide a foundation for the development of more effective and targeted therapeutic agents. By studying the compound's interactions with biological targets, researchers can gain insights into the design principles for creating more potent and selective drugs.
Used in Chemical Synthesis:
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one can also be utilized in chemical synthesis as a starting material or intermediate for the production of other complex organic molecules. Its unique structure and functional groups make it an attractive candidate for the synthesis of novel compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

Upstream product

• 536-74-3 phenylacetylene 
• 1375754-06-5 (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one 
• 85117-99-3 2-(bromomethyl)-1,4-difluorobenzene 
• 2646-90-4 2,5-difluorobenzaldehyde 

Relevant academic research and scientific papers

Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5

Positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 5 (mGluR5) are of interest due to their potential therapeutic utility in schizophrenia and other cognitive disorders. Herein we describe the discovery and optimization of a novel oxazolidinone-based chemotype to identify BMS-955829 (4), a compound with high functional PAM potency, excellent mGluR5 binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype. The low fold shift and absence of agonist activity proved critical in the identification of a molecule with an acceptable preclinical safety profile. Despite its low fold shift, 4 retained efficacy in set shifting and novel object recognition models in rodents.

Enantioselective Synthesis of a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 5 (mGluR5) Receptor via Dynamic Kinetic Resolution of α-Amino Ketones

The concise synthesis of a pharmaceutical candidate is described. The chiral core of the molecule is assembled using an aza-benzoin condensation and a dynamic kinetic resolution (DKR) as the key reactions. This enables superb control of the regio-, diastereo- and enantioselectivity of the synthesis. Both biocatalysts and transition metal catalysts are remarkably effective in the key asymmetric reduction step. Similar approaches could be considered in the synthesis of other 1,2-amino alcohols where traditional approaches based on functionalization of alkenes, epoxides or aziridines may suffer from selectivity issues. (Figure presented.) .

OXAZOLIDINONES AS MODULATORS OF MGLUR5

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.